Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04775082 · ClinicalTrials.gov registry record · Phase 3
SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity
A Phase 3 study of Obesity, sponsored by Novo Nordisk A/S.
- Active
- Registry status
- Phase 3
- Development phase
- 78
- Enrollment target
- 20
- Study locations
NCT04775082: Active Phase 3 study of Obesity, sponsored by Novo Nordisk A/S.
NCT04775082 is a Phase 3 study of Obesity that is active but no longer recruiting, run by Novo Nordisk A/S. The registered enrollment target is 78 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04775082, a Phase 3 study of Obesity, is active but no longer recruiting, sponsored by Novo Nordisk A/S.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 78 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study looks at how liraglutide works on participant's body weight. Researchers will look at how liraglutide can help children with obesity to lose weight. They will look at how much weight the children will lose, and if there are any side effects. Participants will either get liraglutide or placebo. Which treatment the participants get is decided by chance. Liraglutide is a new medicine for children, but it can already be prescribed by doctors to adults with overweight or obesity. The participant will get 1 injection every day. In addition to taking the medicine, the participants will have talks with the study staff about healthy food choices, how they can be more physically active and what can be done to help the participants to lose weight. The study will last for about 96 weeks (almost 2 years). The participants will have 18 clinic visits and 10 phone or video calls with the study doctor/staff. Participant will have blood samples taken, have 1 test to check the heart, 1 hand X-ray taken and must fill in a diary between some of the visits.
Primary Outcome
Percent
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Liraglutide
Study Locations (20)
Other
- UZ Brussel - Brussels
- UZ Leuven - Kindergeneeskunde - Leuven
- Mamc & Lnjp - New Delhi
- Rambam MC - Department of Pediatrics A - Haifa
- Schneider MC - Endrocrinology and Diabetes - Petah Tikva
- Hospital Putrajaya - Putrajaya
- Consultorio de Endocrinología y Pediatría - Puebla City
- Hospital Da Luz S.A. - Lisbon
- Hospital da Luz - Lisbon
Arizona
- TMC Hlthcr Clin Res Office - Tucson
Colorado
- Children's Hospital Colorado - Denver
Idaho
- Solaris Clinical Research - Meridian
Louisiana
- Pennington Biom Res Ctr - Baton Rouge
Maryland
- Barry J. Reiner, MD LLC - Baltimore
Minnesota
- University of Minnesota_CPOM - Minneapolis
New York
- UBMD Peds-Div of Endo/Diabetes - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2021-03-04 |
| Est. Completion | 2027-01-15 |
| Phase | Phase 3 |
What the registry record for NCT04775082 still lists
NCT04775082 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04775082 names 20 study sites across 12 states, led by Other, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT04775082 about?
NCT04775082 is a clinical study titled "SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity". The study looks at how liraglutide works on participant's body weight. Researchers will look at how liraglutide can help children with obesity to lose weight. They will look at how much weight the children will lose, and if there are any side effects. Participants will either get liraglutide or pla...
What is the current status of trial NCT04775082?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 78 participants. The study started on 2021-03-04. Estimated completion is 2027-01-15.
What conditions does trial NCT04775082 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT04775082?
The interventions under investigation include: Placebo (DRUG), Liraglutide (DRUG).
Who is sponsoring clinical trial NCT04775082?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04775082 being conducted?
This trial has 20 study locations across Arizona, Colorado, Idaho, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04775082's enrollment target sits among peer trials
78 561st of 1053 higher than 491 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI